RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Mar 2019: Trial registered, NCT03863184
  2. 11 Oct 2019: Trial started, NCT03863184

The trials

NCT03863184: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

State
Under way
Phase
Phase 2
People
37 taking part
Started
11 Oct 2019
Primary completion
25 Apr 2024
Arms
ALR in Combination
Results
Posted on the registry
  1. 5 Mar 2019: Trial registered
  2. 11 Oct 2019: Trial started
  3. 6 Jun 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.